Paul Young is the man of the moment.
In one week he has published the SPLIT trial in JAMA, the HEAT trial in the NEJM and presented both at the ESICM conference.
In this interview, Paul discusses The SPLIT Trial – the first trial to substantially look at buffered crystalloids vrs saline and now really paves the way for a definitive trial in this area.
He answers some questions that have been asked such as was the volume of fluid sufficient to demonstrate an effect, why PlasmaLyte was used and what he’ll be doing following these results.
HEAT was a highly anticipated trial looking at the effect of early administration of acetaminophen to treat fever due to probable infection. This intervention did not affect the number of ICU-free days. Paul captured out imagination on this topic with a talk at SMACC in 2013 and following HEAT the dialogue really begins. We discuss where to go from here on this topic that often stimulates passionate debate…
Finally we discuss Platform Trials and how they will save the world. This was topic of a talk Paul gave in Chicago which will be released soon. Read this fascinating paper by Berry Connor and Lewis for a real insight into the hot topic.
[az_box_icon animation_loading=”yes” animation_loading_effects=”move_left” icon=”font-icon-megaphone” title=”The Podcast” position=”left”]
[/az_box_icon][az_box_icon animation_loading=”yes” animation_loading_effects=”move_left” icon=”font-icon-book” title=”More resources” position=”left”]
[az_box_icon animation_loading=”yes” animation_loading_effects=”move_left” icon=”font-icon-question” title=”What is New Zealand?” position=”left”]